Vashi Pankaj, Popiel Brenten, Lammersfeld Carolyn, Gupta Digant
From the Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion, IL.
Pancreas. 2015 Jul;44(5):750-5. doi: 10.1097/MPA.0000000000000336.
We investigated the nutritional and survival outcomes of medical nutrition therapy by a registered dietitian, along with support from a dedicated nutrition and metabolic support team in pancreatic cancer patients requiring enteral or parenteral nutrition.
Subjective global assessment (SGA) was used to assess nutritional status in 304 pancreatic cancer patients. Using baseline and last SGA, patients were categorized into 3 groups: improved SGA, deteriorated SGA, and unchanged SGA. Kaplan-Meier and Cox regression were used to calculate survival after controlling for relevant confounders.
One-hundred twenty-five (41.1%) patients had their SGA unchanged, 87 (28.6%) patients had "improved SGA," whereas 92 (30.3%) patients had "deteriorated SGA." On univariate survival analysis, the median survival was 7.8, 11.2, and 12.6 months for deteriorated, unchanged, and improved SGA groups, respectively. On multivariate analysis, change in SGA was independently predictive of survival. Patients with deteriorated SGA had 1.5 times (95% confidence interval, 1.1-2.1) greater risk of mortality compared to those with improved SGA.
The majority of pancreatic cancer patients (70%) in our study either maintained or improved their nutritional status during cancer treatment. Improvement in SGA correlated with a significantly decreased risk of mortality independent of sex, previous treatment history, and evidence of biological anticancer activity.
我们调查了在注册营养师进行医学营养治疗以及专门的营养与代谢支持团队的支持下,需要肠内或肠外营养的胰腺癌患者的营养和生存结局。
采用主观全面评定法(SGA)评估304例胰腺癌患者的营养状况。根据基线和末次SGA,将患者分为3组:SGA改善组、SGA恶化组和SGA不变组。采用Kaplan-Meier法和Cox回归分析在控制相关混杂因素后计算生存率。
125例(41.1%)患者的SGA不变,87例(28.6%)患者“改善SGA”,而92例(30.3%)患者“恶化SGA”。单因素生存分析显示,SGA恶化组、不变组和改善组的中位生存期分别为7.8个月、11.2个月和12.6个月。多因素分析显示,SGA变化是生存的独立预测因素。与SGA改善的患者相比,SGA恶化的患者死亡风险高1.5倍(95%置信区间,1.1-2.1)。
在我们的研究中,大多数胰腺癌患者(70%)在癌症治疗期间维持或改善了营养状况。SGA的改善与死亡风险显著降低相关,且不受性别、既往治疗史和生物抗癌活性证据的影响。